Development of a Transcription Factor-Based Prognostic Model for Predicting the Immune Status and Outcome in Pancreatic Adenocarcinoma

Figure 4

Development of the TF-based prognostic signature in PAAD. (a–c) Distributions of four-gene expression profiles of each patient, risk scores, and survival statuses of patients in the low-risk and high-risk groups. (d) Kaplan-Meier assays of the TF-related signature displaying worse survivals in the high-risk group. (e) ROC curve is applied to determine the diagnostic value of our model.

(a)

(b)

(c)

(d)

(e)